FDA Requests Comment on Proposed Collection of Information for Compounded Drug Products

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, seeking industry guidance on compounded drug products that are essentially copies of commercially available drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act.